|
|
| | epiyangambin Basic information |
| Product Name: | epiyangambin | | Synonyms: | epiyangambin;(+)-Epipinoresinol dimethyl ether;(1S)-1β,4α-Bis(3,4-dimethoxyphenyl)-3aβ,4,6,6aβ-tetrahydro-1H,3H-furo[3,4-c]furan;(1S,3aβ,6aβ)-1β,4α-Bis(3,4-dimethoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan;(1S,3aβ,6aβ)-Tetrahydro-1β,4α-bis(3,4-dimethoxyphenyl)-1H,3H-furo[3,4-c]furan;[1S,(+)]-1β,4α-Bis(3,4-dimethoxyphenyl)-3aβ,4,6,6aβ-tetrahydro-1H,3H-furo[3,4-c]furan;Lirioresinol A dimethyl ether;O,O-Dimethyllirioresinol A | | CAS: | 24192-64-1 | | MF: | C24H30O8 | | MW: | 446.49 | | EINECS: | | | Product Categories: | | | Mol File: | 24192-64-1.mol |  |
| | epiyangambin Chemical Properties |
| Melting point | 112-114℃ | | Boiling point | 556.120±50.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.183±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| | epiyangambin Usage And Synthesis |
| Uses | Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells)[1][2]. | | in vivo | Epiyangambin (20 mg/kg) significantly inhibits PAF (platelet activating factor)-induced thrombocytopenia in rats[2]. | | References | [1] Hausott B, et al. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol. 2003 Oct;129(10):569-76. DOI:10.1007/s00432-003-0461-7
[2] Castro-Faria-Neto HC, et al. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. J Lipid Mediat. 1993 May;7(1):1-9. PMID:8358020 |
| | epiyangambin Preparation Products And Raw materials |
|